NextCell publishes its Year-End Report 2022/2023

October 26, 2023

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

Fourth quarter (2023-06-01 until 2023-08-31)

● Operating Income amounted to 3,947 (1,405) TSEK.
● Net Income for Cellaviva amounted to 2,758 (1,359) TSEK.
● Operating result amounted to -8,640 (-8,563) TSEK.
● Earnings per share* amounted to -0.25 (-0.25) SEK.
● Cash and bank amounted to 50,025 (97,117) TSEK.
● Solidity amounted to 85.3 (92.7)

Twelve months (2022-09-01 till 2023-08-31)**

● Operating income amounted to 13,955 (6,229) TSEK.
● Net Income for Cellaviva amounted to 10,113 (5,589) TSEK.
● Operating result amounted to -39,812 (-34,554) TSEK.
● Earnings per share* amounted to -1.16 (-1.01) SEK.
● The Board of Directors proposes that no dividend shall be paid for the financial year.

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the fourth quarter 2022/2023: 34,379,523 (34,379,523) shares. Average number of shares for the full year 2022/2023: 34,379,523 (30,411,847) shares. Number of shares in NextCell as of August 31, 2023: 34,379,523 (34,379,523) shares.
**Solidity: Equity to total balance sheet.

Significant events in the fourth quarter

● NextCell announced at the beginning of July that the clinical trial ProTrans 19+SE would start recruiting patients in the high dose group, which is the last dose group. Three patients treated with medium dose of ProTrans have been clinically evaluated and the data has been reviewed by the Data Safety Monitoring Board, which now allows continued treatment with high dose ProTrans for severe pneumonia caused by COVID-19, Influenza, Human metapneumovirus (HMPV), and respiratory syncytial virus (RSV).

Significant events after the reporting period

● NextCell Pharma AB (“NextCell” or “the company”) announces that the company has signed an agreement with the Finnish biotechnology company Linio to warehouse and distribute Tience® in Sweden. The value of the agreement for the first year amounts to approximately 400 000 SEK in fixed remuneration and a variable remuneration per product delivered. Tience is a tissue product that is injected to combat scarring and can also be used for aesthetic purposes such as skin rejuvenation and to combat wrinkles. The product is marketed and sold by Linio to clinics and hospitals.

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 26-10-2023 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma

For more information about Cellaviva, please contact
Sofie Falk Jansson, Head of Cellaviva
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se

Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Certified Adviser
FNCA Sweden AB is assigned as Certified Adviser.

About NextCell Pharma AB
NextCell is a cell therapy company in phase II trials with the drug candidate ProTrans for the treatment of type 1 diabetes. The focus is to obtain market approval of ProTrans via a phase III trial. In addition to type 1 diabetes, ProTrans is used in two clinical trials for COVID-19, in Örebro and in Montreal, Canada. The company is in the process of establishing its own GMP-facility for the production of ProTrans. Furthermore, NextCell owns 8.5% in FamicordTX, a CAR-T start-up in oncology, and 100% of Cellaviva, Scandinavia’s largest private stem cell bank licensed by the Swedish Health Authority (IVO) to preserve and store stem cells from umbilical cord blood and umbilical cord tissue for family use.

Download attachment Read full press release on Cision (external link)

2018-11-28

NextCell CEO invited speaker at Karolinska Institutet Conference

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the Karolinska Institutet conference “From tissue to motion” - a 10-year anniversary. The conference brings together different research groups within the field of regenerative medicine who will meet with entrepreneurs and life science companies for two days. The scope is to cover the very latest progress of the research in the multidisciplinary fields of regenerative medicine, motion and health.

Read more Read more

2018-11-16

ProTrans trial is approved for high dose treatment in the phase II part

The stem cell company NextCell Pharma AB ("NXTCL") today announced that the Swedish Medical Product Agency has approved the amendment for treatment of patients in the ProTrans-1 trial with high dose of ProTrans in the randomized placebo-controlled part. The ProTrans clinical trial is divided into a dose-scale part where 9 patients were treated with ProTrans during 2018. On October 25th, the Data Safety and Monitoring Board recommended the start of the second part of the trial with the dose that the study team found most appropriate. The safety of ProTrans seem well tolerated, NXTCL

Read more Read more

2018-11-14

NextCell Pharma's clinical trial on the TV3 Diabetes gala

Stem cell company NextCell Pharma AB ("NXTCL") announces that the ongoing clinical trial with ProTrans for the treatment of type 1 diabetes, tonight will be highlighted on the Diabetes Gala. A shorter clip will be shown on the gala and a longer version will be available on ViaPlay, Viafree and on the NXTCL website. The broadcast strats at 20:00.

Read more Read more

2018-11-12

Earlier announced directed share issue to Nordic Tech House AB registered at the Swedish Companies Registrations Office

NextCell Pharma AB ("NextCell") hereby announces that the directed share issue to Nordic Tech House AB (”NTH”) has been registered at the Swedish Companies Registrations Office (Bolagsverket). The newly issued shares are under lock-up. In total, 260 100 shares have been issued at a subscription price of SEK 5.767 per share, equivalent to 2.3 percent of votes and capital in NXTCL. The shares will be settled retrospectively. After the registration at the Swedish Companies Registrations Office, the total amount of shares in NXTCL are 11 486 456 and the share capital is SEK 2 354 723,48. NTH has

Read more Read more

2018-11-09

Publication of annual report 2017/2018

NextCell Pharma AB hereby, on November 9th, 2018, publishes the annual report for the fiscal year 2017/2018. The annual report is available on the company’s website (www.nextcellpharma.com) and Spotlight Stock Market’s website (www.spotlightstockmarket.com).

Read more Read more

2018-11-05

Application for clinical trial submitted to the Medical Products Agency, ProTrans-2.

NextCell Pharma AB ("NXTCL") today announced that a new application to conduct a clinical trial with ProTrans has been submitted to the Swedish Medical Products Agency. The purpose of the study is to evaluate repeated treatment with ProTrans, including patients with type 1 diabetes who participated in the dose escalating part of the original NXTCL trial. The ongoing clinical trial called ProTrans-1, was initiated with a dose escalation phase for 9 patients all followed for 12 months. After their last visit in the study, patients will be asked if they want to participate in a new study where

Read more Read more

2018-11-02

Update regarding targeted new issue to Nordic Tech House

NextCell Pharma (NXTCL), announces today that the Board, with the authorization of the Annual General Meeting of December 5, 2017, has decided to implement a directed new issue of Nordic Tech House AB ("NTH") of a maximum of approximately SEK 1.5 million. The reasons for the deviation from shareholders' pre-emption rights are to fulfil the company's commitment in accordance with an agreement with Nordic Tech House AB, which was concluded to provide the company with new owners of strategic importance. Current decision replaces previous resolutions on directed new issue from March 13, 2018,

Read more Read more

2018-10-31

Publication of year-end report

NextCell Pharma AB (”NXTCL”, “NextCell”) today, released its year-end report for book year 2017/2018 (September 2017 – August 2018). Twelve Months (2017-09-01 until 2018-08-31) · Net sales amounted to SEK 655 413 (517 203). · Operating result amounted to SEK –14 032 294 (-13 245 206). · Result per share amounted to SEK -0,61 (-0,64). · Cash and bank amounted to SEK 3 115 876 (16 600 937). · Solidity amounted to 59 (88) %. · Net sales amounted to SEK 127 868 (198 765). · Operating result amounted to SEK -3 422 282 (-4 757 996).

Read more Read more